U.S., Dec. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07266298) titled 'TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors' on Nov. 18.
Brief Summary: This clinical trial is a prospective, dose-escalation, multicenter, single- arm, Phase 1 clinical trial to evaluate the safety, tolerability, PK and preliminary clinical activity of PRAME Antigen-targeted TCR-T Cells (NW-101C) infusion in patients with previously heavily treated, metastatic solid malignant tumors.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Solid Metastatic Tumor
Intervention:
DRUG: NW-101C
TCR-T cell targeting PRAME antigen
Recruitment Status: RECRUITING
Sponsor: Neowise Biotechnology...